Tvardi Therapeutics Statistics
Share Statistics
Tvardi Therapeutics has 9.36M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 9.36M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 9.55K, so 0% of the outstanding
shares have been sold short.
| Short Interest | 9.55K |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -2.64 and the forward
PE ratio is -8.85.
Tvardi Therapeutics's PEG ratio is
0.17.
| PE Ratio | -2.64 |
| Forward PE | -8.85 |
| PS Ratio | 0 |
| Forward PS | 9.2 |
| PB Ratio | -0.74 |
| P/FCF Ratio | -2.18 |
| PEG Ratio | 0.17 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Tvardi Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.97,
with a Debt / Equity ratio of -0.01.
| Current Ratio | 7.97 |
| Quick Ratio | 7.97 |
| Debt / Equity | -0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,020,411.76 |
| Employee Count | 17 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 0.21, so Tvardi Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.21 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 65 |
| Average Volume (20 Days) | 21,326 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -18.66M |
| Net Income | -17.35M |
| EBITDA | -17.25M |
| EBIT | -17.35M |
| Earnings Per Share (EPS) | -1.85 |
Full Income StatementBalance Sheet
The company has 22.92M in cash and 368K in
debt, giving a net cash position of 22.55M.
| Cash & Cash Equivalents | 22.92M |
| Total Debt | 368K |
| Net Cash | 22.55M |
| Retained Earnings | -62.84M |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -21.04M
and capital expenditures 0, giving a free cash flow of -21.04M.
| Operating Cash Flow | -21.04M |
| Capital Expenditures | n/a |
| Free Cash Flow | -21.04M |
| FCF Per Share | -2.25 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
